Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 2 | 2022 | 346 | 1.050 |
Why?
|
| Exercise Test | 2 | 2022 | 164 | 0.980 |
Why?
|
| Hemangioma, Capillary | 1 | 2022 | 7 | 0.850 |
Why?
|
| Pulmonary Veno-Occlusive Disease | 1 | 2022 | 7 | 0.840 |
Why?
|
| Lung | 4 | 2022 | 1168 | 0.780 |
Why?
|
| Epoprostenol | 1 | 2020 | 46 | 0.720 |
Why?
|
| Drug Substitution | 1 | 2020 | 25 | 0.720 |
Why?
|
| Lung Diseases | 1 | 2022 | 263 | 0.710 |
Why?
|
| Tuberculosis, Miliary | 1 | 2017 | 4 | 0.630 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2017 | 7 | 0.610 |
Why?
|
| Bronchiectasis | 1 | 2017 | 13 | 0.600 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2587 | 0.600 |
Why?
|
| Splenectomy | 1 | 2016 | 82 | 0.560 |
Why?
|
| Bronchi | 1 | 2017 | 229 | 0.550 |
Why?
|
| Thromboembolism | 1 | 2016 | 119 | 0.530 |
Why?
|
| Antihypertensive Agents | 1 | 2020 | 521 | 0.520 |
Why?
|
| Quality of Life | 1 | 2022 | 1585 | 0.490 |
Why?
|
| Macrophages, Alveolar | 4 | 2022 | 55 | 0.450 |
Why?
|
| Venous Thrombosis | 1 | 2016 | 243 | 0.450 |
Why?
|
| Echocardiography | 2 | 2022 | 911 | 0.280 |
Why?
|
| Glycolysis | 3 | 2022 | 129 | 0.270 |
Why?
|
| Radiography, Thoracic | 2 | 2017 | 320 | 0.260 |
Why?
|
| Inflammation | 2 | 2020 | 923 | 0.240 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1564 | 0.220 |
Why?
|
| Acute Lung Injury | 1 | 2022 | 60 | 0.200 |
Why?
|
| Pneumonia, Aspiration | 1 | 2021 | 19 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 28 | 0.200 |
Why?
|
| Klebsiella Infections | 1 | 2021 | 25 | 0.200 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2020 | 15 | 0.190 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 29 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 95 | 0.190 |
Why?
|
| Succinates | 1 | 2020 | 21 | 0.190 |
Why?
|
| Carboxy-Lyases | 1 | 2020 | 22 | 0.180 |
Why?
|
| Infusions, Subcutaneous | 1 | 2020 | 3 | 0.180 |
Why?
|
| Mycoses | 1 | 2020 | 46 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 41 | 0.180 |
Why?
|
| Walk Test | 1 | 2020 | 21 | 0.180 |
Why?
|
| Macrophage Activation | 1 | 2020 | 48 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 56 | 0.180 |
Why?
|
| Critical Care Nursing | 1 | 2019 | 4 | 0.180 |
Why?
|
| Administration, Inhalation | 1 | 2020 | 188 | 0.170 |
Why?
|
| Particulate Matter | 1 | 2020 | 79 | 0.170 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 429 | 0.170 |
Why?
|
| Behavior Therapy | 1 | 2019 | 75 | 0.170 |
Why?
|
| Humans | 11 | 2022 | 86656 | 0.170 |
Why?
|
| Bacterial Infections | 1 | 2020 | 182 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2020 | 301 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2020 | 181 | 0.160 |
Why?
|
| Cardiac Catheterization | 1 | 2020 | 291 | 0.160 |
Why?
|
| Macrophages | 1 | 2021 | 557 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2020 | 460 | 0.150 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 48 | 0.150 |
Why?
|
| Fibroblasts | 1 | 2020 | 729 | 0.150 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 148 | 0.140 |
Why?
|
| Cell-Derived Microparticles | 1 | 2016 | 11 | 0.140 |
Why?
|
| Bronchoscopy | 1 | 2017 | 152 | 0.140 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 246 | 0.140 |
Why?
|
| Liver | 1 | 2021 | 1228 | 0.140 |
Why?
|
| Male | 7 | 2020 | 40984 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 930 | 0.130 |
Why?
|
| Middle Aged | 5 | 2020 | 25036 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 680 | 0.120 |
Why?
|
| Electric Countershock | 1 | 2014 | 47 | 0.120 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2014 | 58 | 0.120 |
Why?
|
| Biopsy | 1 | 2017 | 1163 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1056 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2016 | 973 | 0.110 |
Why?
|
| Receptors, Complement 3d | 1 | 2011 | 14 | 0.100 |
Why?
|
| Agammaglobulinemia | 1 | 2011 | 20 | 0.100 |
Why?
|
| Stroke Volume | 1 | 2014 | 456 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2014 | 288 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 462 | 0.090 |
Why?
|
| Aged | 4 | 2020 | 18421 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 1037 | 0.070 |
Why?
|
| Adult | 4 | 2020 | 25657 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 724 | 0.070 |
Why?
|
| Oxygen | 2 | 2022 | 726 | 0.070 |
Why?
|
| Risk Factors | 1 | 2016 | 5420 | 0.070 |
Why?
|
| Female | 4 | 2020 | 44547 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 6513 | 0.060 |
Why?
|
| Mice | 3 | 2022 | 11356 | 0.060 |
Why?
|
| Macrophages, Peritoneal | 1 | 2021 | 21 | 0.050 |
Why?
|
| Colony Count, Microbial | 1 | 2021 | 46 | 0.050 |
Why?
|
| Animals | 4 | 2022 | 26590 | 0.050 |
Why?
|
| Primary Cell Culture | 1 | 2021 | 72 | 0.050 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2022 | 151 | 0.050 |
Why?
|
| Peritoneum | 1 | 2021 | 57 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2021 | 34 | 0.050 |
Why?
|
| Phagocytosis | 1 | 2021 | 86 | 0.050 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 22 | 0.050 |
Why?
|
| Glycine | 1 | 2020 | 92 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2021 | 258 | 0.050 |
Why?
|
| Serine | 1 | 2020 | 99 | 0.050 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 49 | 0.050 |
Why?
|
| Spleen | 1 | 2021 | 430 | 0.050 |
Why?
|
| Cell Survival | 1 | 2022 | 969 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2020 | 239 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2020 | 3243 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2020 | 262 | 0.040 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2021 | 194 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 182 | 0.040 |
Why?
|
| Collagen | 1 | 2020 | 269 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 322 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2020 | 227 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 286 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2021 | 480 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 409 | 0.040 |
Why?
|
| Inpatients | 1 | 2020 | 298 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 641 | 0.040 |
Why?
|
| Mitochondria | 1 | 2020 | 535 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 512 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2020 | 1924 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2231 | 0.030 |
Why?
|
| Complement C3d | 1 | 2011 | 6 | 0.030 |
Why?
|
| Viral Matrix Proteins | 1 | 2011 | 14 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2014 | 478 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 2011 | 87 | 0.030 |
Why?
|
| Transgenes | 1 | 2011 | 180 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 67 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 205 | 0.020 |
Why?
|
| Calcium Signaling | 1 | 2011 | 129 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2011 | 152 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 526 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2011 | 615 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1457 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 3642 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2020 | 8495 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2014 | 4215 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2014 | 2206 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 5980 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 7998 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 8984 | 0.010 |
Why?
|